IN8bio, Inc. Common Stock (INAB) is a publicly traded Healthcare sector company. As of May 21, 2026, INAB trades at $1.59 with a market cap of $13.98M and a P/E ratio of -0.58. INAB moved +4.14% today. Year to date, INAB is -36.44%; over the trailing twelve months it is -59.74%. Its 52-week range spans $1.17 to $16.70. Analyst consensus is strong buy with an average price target of $5.00. Rallies surfaces INAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IN8bio Achieves 18× Intratumoral CD8+ Boost and 97% PFS Gain in glioblastoma: IN8bio’s translational data show multidose DeltEx DRI preserved CD3+, CD4+, CD8+ and γδ T cells during TMZ therapy and drove an 18× intratumoral CD8+ T cell increase with 90% granulocyte reduction. These immune changes align with mPFS of 13.0 months versus 6.6 months and mOS exceeding 17.2+ months.
| Metric | Value |
|---|---|
| Price | $1.59 |
| Market Cap | $13.98M |
| P/E Ratio | -0.58 |
| EPS | $-2.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.70 |
| 52-Week Low | $1.17 |
| Volume | 240 |
| Avg Volume | 0 |
| Revenue (TTM) | $487.00K |
| Net Income | $-18.98M |
| Gross Margin | 0.00% |
3 analysts cover INAB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.00.